Selumetinib Shrinks NF1-Plexiform Neurofibromas in Adults, Too

By News Health
3 months Ago

(MedPage Today) — CHICAGO — Selumetinib (Koselugo) significantly improved response rates in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas, the phase III KOMET trial showed.
After 16 cycles…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115874

Author :

Publish date : 2025-06-03 15:43:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Deeper Cuts at HHS; Food Safety Rollbacks; Old Paxil Study Scrutinized

Patients struggle to get weight loss drug ahead of price rise

Global Prevalence of Hidradenitis Suppurativa Near 1%

Policy Lag on HIV, Breastfeeding Persists in Latin America

SpaceX's Starship rocket finally completes successful test flight

Obeldesivir Shows Mixed Results in COVID